Lipid Metabolism — MCQs

Lipid Metabolism Indian Medical PG Practice Questions and MCQs

Question 41: What is the hydrogenation of a fatty acid?

A. Hydrolysis by alkali
B. Auto-oxidation of polyunsaturated fatty acid
C. Addition of hydrogen to an unsaturated fatty acid (Correct Answer)
D. Addition of hydrogen to a saturated fatty acid

Explanation: ### Explanation **Correct Answer: C. Addition of hydrogen to an unsaturated fatty acid** **Concept Breakdown:** Hydrogenation is a chemical process where **hydrogen atoms are added** across the double bonds of **unsaturated fatty acids**. This reaction is typically catalyzed by metals like nickel. By converting double bonds ($C=C$) into single bonds ($C-C$), the fatty acid becomes more "saturated." This process increases the melting point of the lipid, turning liquid oils into solid or semi-solid fats (e.g., converting vegetable oil into margarine/vanaspati ghee). **Analysis of Incorrect Options:** * **Option A (Hydrolysis by alkali):** This describes **Saponification**. When triglycerides are hydrolyzed by an alkali (like $NaOH$ or $KOH$), they form glycerol and salts of fatty acids (soap). * **Option B (Auto-oxidation of PUFA):** This describes **Lipid Peroxidation** or **Rancidification**. It involves the non-enzymatic oxidation of polyunsaturated fatty acids (PUFAs) by free radicals, leading to the formation of malondialdehyde and off-flavors. * **Option D (Addition of hydrogen to a saturated fatty acid):** This is chemically impossible. Saturated fatty acids contain only single bonds and are already "saturated" with the maximum number of hydrogen atoms possible. **NEET-PG High-Yield Pearls:** * **Trans-Fats:** Partial hydrogenation is the primary industrial source of **trans-fatty acids**. These are clinically significant as they raise LDL ("bad" cholesterol) and lower HDL ("good" cholesterol), significantly increasing the risk of Coronary Artery Disease (CAD). * **Essential Fatty Acids:** Humans lack the enzymes to introduce double bonds beyond carbon 9 and 10; hence, Linoleic and Linolenic acids must be obtained from the diet. * **Iodine Number:** This is a laboratory measure used to determine the degree of unsaturation in a fat. A higher iodine number indicates more double bonds.

Question 42: Which of the following enzymes is absent in Wolman's disease?

A. Cholesterol ester hydrolase
B. Acid hydrolase
C. Acyl-CoA carnitine
D. Acid lipase (Correct Answer)

Explanation: **Explanation:** **Wolman’s Disease** is a rare, autosomal recessive lysosomal storage disorder characterized by a severe deficiency of the enzyme **Lysosomal Acid Lipase (LAL)**. 1. **Why Acid Lipase is correct:** Under normal physiological conditions, LAL is responsible for the hydrolysis of cholesteryl esters and triglycerides (delivered via LDL) into free cholesterol and free fatty acids within the lysosomes. In Wolman’s disease, the absence of this enzyme leads to the massive accumulation of these lipids in various organs, particularly the liver, spleen, and adrenal glands. 2. **Why other options are incorrect:** * **Cholesterol ester hydrolase:** While LAL functions as a hydrolase for cholesterol esters, the specific clinical name for the deficient enzyme in this pathology is Acid Lipase. * **Acid hydrolase:** This is a broad category of enzymes found in lysosomes (including proteases, nucleases, etc.). It is not a specific enzyme name. * **Acyl-CoA carnitine:** This refers to the carnitine shuttle system (CPT-1/CPT-2) involved in the transport of long-chain fatty acids into the mitochondria for beta-oxidation, unrelated to lysosomal storage. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Sign:** Bilateral **adrenal calcification** is a classic radiological finding in Wolman’s disease. * **Clinical Presentation:** Infants typically present with hepatosplenomegaly, steatorrhea, and failure to thrive. It is usually fatal within the first year of life. * **Related Condition:** **Cholesteryl Ester Storage Disease (CESD)** is a milder, later-onset form of LAL deficiency where some residual enzyme activity remains. * **Gene Mutation:** Mutations occur in the *LIPA* gene located on chromosome 10.

Question 43: Which of the following conditions is characterized by high HDL cholesterol?

A. Abetalipoproteinemia
B. Hyperalphalipoproteinemia (Correct Answer)
C. Sitosterolemia
D. Dysbetalipoproteinemia

Explanation: **Explanation:** The correct answer is **Hyperalphalipoproteinemia**. **1. Why Hyperalphalipoproteinemia is correct:** In lipoprotein electrophoresis, **HDL (High-Density Lipoprotein)** migrates to the **alpha-globulin** position. Therefore, "Hyperalphalipoproteinemia" literally translates to high levels of alpha-lipoproteins (HDL) in the blood. This is often a beneficial genetic condition (Familial Hyperalphalipoproteinemia) associated with a reduced risk of atherosclerosis and coronary artery disease. It can be caused by a deficiency in **Cholesteryl Ester Transfer Protein (CETP)**, which normally transfers cholesterol from HDL to VLDL/LDL. **2. Why the other options are incorrect:** * **Abetalipoproteinemia:** This is a deficiency of Microsomal Triglyceride Transfer Protein (MTP), leading to an inability to synthesize Apo-B48 and Apo-B100. This results in **near-zero levels** of Chylomicrons, VLDL, and LDL. * **Sitosterolemia:** A rare plant sterol storage disease caused by mutations in ABCG5/G8 transporters. It is characterized by increased absorption of plant sterols (like sitosterol) and normal or slightly elevated LDL, but not high HDL. * **Dysbetalipoproteinemia (Type III Hyperlipoproteinemia):** Characterized by a deficiency in **Apo-E**, leading to the accumulation of Chylomicron remnants and IDL (Broad-beta band). It typically presents with high cholesterol and triglycerides, not high HDL. **High-Yield NEET-PG Pearls:** * **HDL** is the "Good Cholesterol" because it mediates **Reverse Cholesterol Transport** via **Apo A-I**. * **CETP Inhibition** is a pharmacological target to raise HDL levels. * **Tangier Disease** is the clinical opposite: characterized by **extremely low HDL** due to a defect in the **ABCA1 transporter**. * **Electrophoresis Mobility:** HDL (Alpha) > VLDL (Pre-beta) > LDL (Beta) > Chylomicrons (Origin).

Question 44: Which of the following organs cannot utilize fatty acids for energy, except?

A. Liver
B. Muscle
C. Brain (Correct Answer)
D. Kidney

Explanation: **Explanation:** The correct answer is **C. Brain**. The primary reason the brain cannot utilize long-chain fatty acids for energy is the **Blood-Brain Barrier (BBB)**. Fatty acids circulate in the blood bound to albumin; this bulky complex cannot cross the BBB. Furthermore, the brain lacks significant levels of the enzymes required for **beta-oxidation**, and relying on fatty acid oxidation would be metabolically risky as it consumes high amounts of oxygen and can generate harmful reactive oxygen species (ROS). During starvation, the brain adapts by using **ketone bodies** (acetoacetate and beta-hydroxybutyrate), which are water-soluble and can cross the BBB, but it never utilizes fatty acids directly. **Analysis of Incorrect Options:** * **A. Liver:** The liver is the central hub for fatty acid metabolism. It actively performs beta-oxidation to provide energy for gluconeogenesis. * **B. Muscle:** Both skeletal and cardiac muscles are major consumers of fatty acids, especially during resting states or prolonged low-intensity exercise. * **D. Kidney:** The renal cortex utilizes fatty acids as its preferred fuel source to meet the high energy demands of tubular reabsorption. **High-Yield NEET-PG Pearls:** * **RBCs** also cannot utilize fatty acids because they lack **mitochondria** (the site of beta-oxidation). * The brain's absolute requirements are **Glucose** (normal state) and **Ketone Bodies** (starvation). * **Essential Fatty Acids:** Linoleic and Linolenic acid must be provided in the diet as humans lack enzymes to introduce double bonds beyond carbon 9.

Question 45: Hypercholesterolemia is commonly associated with which of the following conditions?

A. Diabetes mellitus
B. Hypothyroidism
C. Nephrotic syndrome
D. All of the above (Correct Answer)

Explanation: **Explanation:** Hypercholesterolemia is a hallmark of several secondary dyslipidemias. The correct answer is **All of the above** because each condition disrupts lipid metabolism through distinct biochemical pathways: 1. **Diabetes Mellitus:** Insulin deficiency or resistance leads to increased lipolysis in adipose tissue, flooding the liver with free fatty acids. This results in increased synthesis of VLDL, which is subsequently converted to LDL. Furthermore, insulin is required for the activation of **Lipoprotein Lipase (LPL)**; its deficiency impairs the clearance of triglyceride-rich lipoproteins. 2. **Hypothyroidism:** Thyroid hormones (T3/T4) are essential for the expression of **LDL receptors** on hepatocytes. In hypothyroidism, a decrease in these receptors leads to reduced clearance of LDL from the circulation, causing a significant rise in serum cholesterol levels. 3. **Nephrotic Syndrome:** The massive urinary loss of albumin triggers a compensatory increase in hepatic protein synthesis. As the liver ramps up production to offset low oncotic pressure, it non-specifically increases the synthesis of lipoproteins (VLDL and LDL), leading to profound hypercholesterolemia. **Clinical Pearls for NEET-PG:** * **Type IIa Hyperlipoproteinemia** is characterized by isolated elevation of LDL (Cholesterol). * **Xanthomas:** Tuberous and tendinous xanthomas (especially of the Achilles tendon) are clinical markers of severe hypercholesterolemia. * **Rule of Thumb:** Always exclude secondary causes like hypothyroidism or nephrotic syndrome before diagnosing a primary (genetic) lipid disorder. * **Statins** are the drug of choice as they inhibit **HMG-CoA Reductase**, the rate-limiting enzyme of cholesterol synthesis.

Question 46: Which of the following is true about mitochondrial chain elongation of fatty acids?

A. Operates under aerobic conditions
B. Is a common pathway
C. Requires pyridoxal-phosphate & NADPH
D. None of the above (Correct Answer)

Explanation: **Explanation:** Fatty acid synthesis primarily occurs via the **De Novo pathway** in the cytoplasm. However, for the synthesis of longer-chain fatty acids, the body utilizes elongation systems. There are two distinct systems: the **Microsomal system** (predominant) and the **Mitochondrial system**. **Why "None of the above" is correct:** The mitochondrial elongation system is essentially the **reversal of beta-oxidation**, with one key difference: the final step uses **NADPH** instead of FADH₂. 1. **Option A is incorrect:** Mitochondrial elongation operates primarily under **anaerobic (hypoxic) conditions**. In aerobic conditions, the mitochondria prioritize beta-oxidation (breakdown) to generate ATP. 2. **Option B is incorrect:** This is **not a common pathway**. The microsomal system (located in the Endoplasmic Reticulum) is the major and most common pathway for elongating fatty acids (e.g., converting Palmitate to Stearate). 3. **Option C is incorrect:** While it requires **NADPH** (and NADH), it **does not require Pyridoxal-phosphate (B6)**. Pyridoxal-phosphate is a co-factor for amino acid metabolism (transamination/decarboxylation), not fatty acid elongation. --- ### **High-Yield Clinical Pearls for NEET-PG:** * **Site of De Novo Synthesis:** Cytoplasm (Multienzyme complex: Fatty Acid Synthase). * **Rate Limiting Enzyme:** Acetyl-CoA Carboxylase (requires Biotin). * **Microsomal Elongation:** Uses **Malonyl-CoA** as the carbon donor and **NADPH** as the reducing power. This is the physiologically dominant elongation pathway. * **Mitochondrial Elongation:** Uses **Acetyl-CoA** as the carbon donor. It is considered a "minor" pathway used mainly for short-to-medium chain fatty acids. * **Key Reductant:** Remember that **NADPH** is the universal "reductive currency" for biosynthetic pathways, including all forms of fatty acid synthesis and elongation.

Question 47: Trans fatty acids are known to form during which process?

A. Hydrogenation of oils (Correct Answer)
B. Beta oxidation of palmitate
C. Rancidity of fats
D. Prostaglandin biosynthesis

Explanation: **Explanation:** **1. Why Option A is Correct:** Trans fatty acids (TFAs) are primarily formed during the **partial hydrogenation of vegetable oils**. In this industrial process, hydrogen is added to unsaturated liquid oils (like soybean or sunflower oil) in the presence of a catalyst (e.g., Nickel) to make them solid at room temperature and increase their shelf life. While the goal is to saturate the double bonds, some cis-double bonds are unintentionally isomerized into the **trans configuration**, resulting in trans fats. **2. Why Other Options are Incorrect:** * **B. Beta-oxidation of palmitate:** This is the catabolic pathway where fatty acids are broken down into Acetyl-CoA units to generate energy. It does not involve the isomerization of double bonds into the trans form. * **C. Rancidity of fats:** This refers to the oxidation (oxidative rancidity) or hydrolysis (hydrolytic rancidity) of fats leading to unpleasant odors. While it damages fats, its primary products are aldehydes, ketones, and free fatty acids, not trans-isomerization. * **D. Prostaglandin biosynthesis:** Prostaglandins are synthesized from arachidonic acid (a polyunsaturated fatty acid) via the cyclooxygenase (COX) pathway. These molecules maintain specific cis-configurations or cyclic structures. **3. High-Yield Clinical Pearls for NEET-PG:** * **Health Impact:** Trans fats are highly atherogenic. They **increase LDL** (bad cholesterol) and **decrease HDL** (good cholesterol), significantly raising the risk of Coronary Artery Disease (CAD). * **Natural Sources:** While most trans fats are industrial, small amounts occur naturally in the milk and meat of ruminants (e.g., vaccenic acid) due to bacterial fermentation in the rumen. * **Biochemical Structure:** In trans fatty acids, the hydrogen atoms are on opposite sides of the double bond, making the chain linear and similar to saturated fats in physical properties.

Question 48: Which vitamin is a component of the fatty acid synthase complex?

A. Pyridoxine
B. Folate
C. Pantothenate (Correct Answer)
D. Thiamine

Explanation: **Explanation:** The **Fatty Acid Synthase (FAS) complex** is a multi-enzyme system responsible for the de novo synthesis of palmitate from acetyl-CoA and malonyl-CoA. **Why Pantothenate is correct:** Pantothenate (Vitamin B5) is a vital precursor for the synthesis of **Coenzyme A (CoA)** and **4'-phosphopantetheine**. In the FAS complex, 4'-phosphopantetheine serves as the prosthetic group for the **Acyl Carrier Protein (ACP)**. It acts as a "flexible arm" that carries the growing fatty acyl chain between the different catalytic sites of the enzyme complex. Without pantothenate, the ACP cannot function, and fatty acid synthesis ceases. **Why the other options are incorrect:** * **Pyridoxine (B6):** Primarily acts as a cofactor (PLP) for transamination, decarboxylation, and heme synthesis. It is not involved in fatty acid synthesis. * **Folate (B9):** Essential for one-carbon metabolism, DNA synthesis, and amino acid metabolism (e.g., conversion of homocysteine to methionine). * **Thiamine (B1):** Acts as a cofactor (TPP) for oxidative decarboxylation (e.g., Pyruvate Dehydrogenase) and the transketolase reaction in the HMP shunt. **High-Yield NEET-PG Pearls:** * **FAS Complex Structure:** In humans, it is a **homodimer**; each monomer contains 7 enzyme activities and one ACP. * **Reducing Power:** **NADPH** is the essential electron donor for fatty acid synthesis, primarily sourced from the HMP shunt. * **Rate-limiting step:** The conversion of Acetyl-CoA to Malonyl-CoA by **Acetyl-CoA Carboxylase (ACC)**, which requires **Biotin (B7)**. * **Location:** Fatty acid synthesis occurs in the **cytosol**, whereas beta-oxidation occurs in the mitochondria.

Question 49: Which of the following accumulates in the body in type 3 Hyperlipoproteinemia?

A. LDL
B. HDL
C. Chylomicron remnants (Correct Answer)
D. Chylomicron

Explanation: **Explanation:** **Type 3 Hyperlipoproteinemia** (also known as **Dysbetalipoproteinemia** or Broad Beta Disease) is caused by a deficiency or polymorphism in **Apolipoprotein E (Apo E)**. 1. **Why Chylomicron Remnants are correct:** Apo E is the essential ligand required for the liver to recognize and clear **Chylomicron remnants** and **IDL (VLDL remnants)** via the LDL-receptor-related protein (LRP). In Type 3, the defective Apo E (specifically the E2/E2 isoform) prevents this uptake, leading to the accumulation of both Chylomicron remnants and IDL in the plasma. 2. **Why other options are incorrect:** * **LDL:** Accumulates in Type 2a (Familial Hypercholesterolemia) due to LDL receptor deficiency. * **HDL:** This is "good cholesterol"; its accumulation is not a feature of standard hyperlipoproteinemias. * **Chylomicrons:** These accumulate in Type 1 (Familial Chylomicronemia) due to Lipoprotein Lipase (LPL) or Apo C-II deficiency. **Clinical Pearls for NEET-PG:** * **Electrophoresis Pattern:** Shows a characteristic **"Broad Beta Band"** (due to overlapping of IDL and VLDL). * **Clinical Sign:** Pathognomonic **Palmar Xanthomas** (Xanthoma striatum palmare) and tuberous xanthomas on elbows/knees. * **Genetics:** Autosomal recessive inheritance of the **Apo E2/E2** phenotype. * **Risk:** Significant increase in premature atherosclerotic cardiovascular disease and peripheral vascular disease.

Question 50: Which of the following apoproteins activate the esterification of cholesterol?

A. Apo E
B. Apo C
C. Apo A1 (Correct Answer)
D. Apo B100

Explanation: ### Explanation The correct answer is **Apo A1**. **1. Why Apo A1 is correct:** Apo A1 is the primary structural protein of **High-Density Lipoprotein (HDL)**. Its most critical functional role is the activation of the enzyme **Lecithin-Cholesterol Acyltransferase (LCAT)**. LCAT catalyzes the esterification of free cholesterol (on the surface of HDL) into cholesterol esters (which move into the core). This process is essential for **Reverse Cholesterol Transport**, allowing HDL to mature from a discoid shape to a spherical shape and effectively carry cholesterol from peripheral tissues back to the liver. **2. Why the other options are incorrect:** * **Apo E:** Primarily serves as a ligand for the **LDL receptor** and the **LRP (LDL Receptor-related Protein)**. It is crucial for the hepatic uptake of chylomicron remnants and IDL. * **Apo C:** This family has diverse roles; most notably, **Apo C-II** is the essential activator of **Lipoprotein Lipase (LPL)**, which hydrolyzes triglycerides in chylomicrons and VLDL. **Apo C-III** inhibits LPL. * **Apo B100:** The structural protein for VLDL, IDL, and LDL. It acts as the primary ligand for the **LDL receptor**, facilitating the endocytosis of LDL into peripheral tissues and the liver. **3. High-Yield Clinical Pearls for NEET-PG:** * **LCAT vs. ACAT:** LCAT (activated by Apo A1) works in the **plasma** (extracellularly), while ACAT (Acyl-CoA:cholesterol acyltransferase) works **intracellularly** to store cholesterol. * **Tangier Disease:** A deficiency in the ABCA1 transporter leads to a near-absence of HDL and Apo A1, characterized by orange tonsils and hepatosplenomegaly. * **Fish-Eye Disease:** A partial deficiency of LCAT leading to corneal opacities.

Practice by Chapter

Lipid Classification and Chemistry

Practice Questions

Fatty Acid Oxidation

Practice Questions

Ketone Body Metabolism

Practice Questions

Fatty Acid Synthesis

Practice Questions

Metabolism of Triacylglycerols

Practice Questions

Phospholipid Metabolism

Practice Questions

Cholesterol Metabolism and Biosynthesis

Practice Questions

Bile Acids and Bile Salts

Practice Questions

Lipoprotein Metabolism and Transport

Practice Questions

Dyslipidemias and Atherosclerosis

Practice Questions

Prostaglandins and Eicosanoids

Practice Questions

Fatty Liver and Lipotropic Factors

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free